Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02	STN pricing information for 2008 now available
NEWS 30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 32	JAN 28	MARPAT searching enhanced
NEWS 33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 35	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:00:50 ON 01 FEB 2008

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:01:15 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 JAN 2008 HIGHEST RN 1001228-41-6
DICTIONARY FILE UPDATES: 31 JAN 2008 HIGHEST RN 1001228-41-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10706328.str



chain nodes :
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46
47 48 49 50
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25
chain bonds :
1-36 2-35 3-34 4-27 7-28 8-11 9-29 10-32 15-33 16-37 17-38 18-20 19-39
21-40 21-41 22-42 22-43 23-26 24-46 24-47 25-44 25-45 26-48 26-49 26-50
28-30 28-31
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-15 12-13 13-14
13-16 14-15 14-19 16-17 17-18 18-19 20-21 20-25 21-22 22-23 23-24 24-25

exact/norm bonds :
5-7 6-10 7-8 7-28 8-9 9-10 9-29 11-12 11-15 12-13 14-15 18-20 20-21
20-25 21-22 22-23 23-24 23-26 24-25
exact bonds :
1-36 2-35 3-34 4-27 8-11 10-32 15-33 16-37 17-38 19-39 21-40 21-41
22-42 22-43 24-46 24-47 25-44 25-45 26-48 26-49 26-50 28-30 28-31
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-16 14-19 16-17 17-18 18-19

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS
37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS
45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 exa
SAMPLE SEARCH INITIATED 15:01:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        7 TO ITERATE

100.0% PROCESSED         7 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            7 TO      298
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA EXA SAM L1

=> s l1 exa full
FULL SEARCH INITIATED 15:02:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      226 TO ITERATE

100.0% PROCESSED       226 ITERATIONS                                  2 ANSWERS
SEARCH TIME: 00.00.01

L3             2 SEA EXA FUL L1

=> d l3

L3   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   692737-81-8  REGISTRY
ED   Entered STN:  14 Jun 2004
CN   2(1H)-Quinolinone-4-14C, 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-
     benzimidazol-2-yl]- (9CI)  (CA INDEX NAME)
MF   C21 H21 F N6 O
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER
```




```
                1 REFERENCES IN FILE CA (1907 TO DATE)
                1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l3 1-2

L3   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   692737-81-8  REGISTRY
ED   Entered STN:  14 Jun 2004
CN   2(1H)-Quinolinone-4-14C, 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-
     benzimidazol-2-yl]- (9CI)  (CA INDEX NAME)
MF   C21 H21 F N6 O
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER
```



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN
RN 405169-16-6 REGISTRY
ED Entered STN: 12 Apr 2002
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (9CI)
OTHER NAMES:
CN 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one
CN Dovitinib
DR 804551-71-1
MF C21 H21 F N6 O
CI COM
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, CASREACT, IMSDRUGNEWS, IMSRESEARCH, PHAR, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

20 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
20 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline caplus wpids uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	66.77	66.98

FILE 'MEDLINE' ENTERED AT 15:02:32 ON 01 FEB 2008

FILE 'CAPLUS' ENTERED AT 15:02:32 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

```
FILE 'WPIDS' ENTERED AT 15:02:32 ON 01 FEB 2008
COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 15:02:32 ON 01 FEB 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l2
SAMPLE SEARCH INITIATED 15:02:36 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED         0 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L4            0 L2

=> s l3
SAMPLE SEARCH INITIATED 15:02:44 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED         0 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L5           41 L3

=> s l5 and (cmax or auc)
L6            2 L5 AND (CMAX OR AUC)

=> d l6 1-2 ibib, abs

L6   ANSWER 1 OF 2  USPATFULL on STN
ACCESSION NUMBER:        2005:299638  USPATFULL
TITLE:                   Inhibition of FGFR3 and treatment of multiple myeloma
INVENTOR(S):             Cai, Shaopei, Seattle, WA, UNITED STATES
                         Chou, Joyce, El Cerrito, CA, UNITED STATES
                         Harwood, Eric, Seattle, WA, UNITED STATES
                         Heise, Carla C., Benicia, CA, UNITED STATES
                         Machajewski, Timothy D., Martinez, CA, UNITED STATES
                         Ryckman, David, Bellevue, WA, UNITED STATES
                         Shang, Xiao, Bellevue, WA, UNITED STATES
                         Wiesmann, Marion, Brisbane, CA, UNITED STATES
                         Zhu, Shuguang, Shoreline, WA, UNITED STATES
PATENT ASSIGNEE(S):      Chiron Corporation (U.S. corporation)

                              NUMBER         KIND    DATE
                         --------------- ------ --------
PATENT INFORMATION:      US 2005261307      A1   20051124
APPLICATION INFO.:       US 2004-983174     A1   20041105  (10)
RELATED APPLN. INFO.:    Continuation-in-part of Ser. No. US 2003-644055, filed
                         on 19 Aug 2003, PENDING

                               NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2003-517915P    20031107 (60)
                         US 2003-526426P    20031202 (60)
```

	US 2003-526425P	20031202 (60)
	US 2004-546017P	20040219 (60)
	US 2002-405729P	20020823 (60)
	US 2002-426107P	20021113 (60)
	US 2002-426226P	20021113 (60)
	US 2002-426282P	20021113 (60)
	US 2002-428210P	20021121 (60)
	US 2003-460328P	20030403 (60)
	US 2003-460493P	20030403 (60)
	US 2003-460327P	20030403 (60)
	US 2003-478916P	20030616 (60)
	US 2003-484048P	20030701 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Page(s)
LINE COUNT: 17221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 2 USPATFULL on STN
ACCESSION NUMBER: 2004:280895 USPATFULL
TITLE: Methods of treating cancer and related methods
INVENTOR(S): Hannah, Alison, Sebastopol, CA, UNITED STATES
Harwood, Eric, Seattle, WA, UNITED STATES
Haroldsen, Peter, Pacifica, CA, UNITED STATES
Heise, Carla, Benecia, CA, UNITED STATES
Machajewski, Timothy, Martinez, CA, UNITED STATES
Samara, Emil, Danville, CA, UNITED STATES
Shang, Xiao, Bellevue, WA, UNITED STATES
Vora, Jayesh, Martinez, CA, UNITED STATES
Zhu, Shuguang, Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004220196	A1	20041104	
APPLICATION INFO.:	US 2003-706328	A1	20031112	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-460369P	20030403 (60)
	US 2003-460493P	20030403 (60)
	US 2003-460328P	20030403 (60)
	US 2002-426204P	20021113 (60)
	US 2002-426282P	20021113 (60)
	US 2002-426107P	20021113 (60)
	US 2003-517915P	20031107 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O.

```
                        Box 8097, Emeryville, CA, 94662-8097
NUMBER OF CLAIMS:       58
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     2 Drawing Page(s)
LINE COUNT:             2045
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Methods of treating cancer using 4-amino-5-fluoro-3-[6-(4-
        methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one are
        provided. In particular, the methods are effective for the treatment of
        solid tumors or leukemias, including prostate, colorectal, breast,
        multiple myeloma, pancreatic, small cell carcinoma, acute myelogenous
        leukemia, chronic myelogenous leukemia, or myelo-proliferative disease.
        Further provided are methods of measuring the amount of
        4-amino-5-fluoro-3-[6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-
        yl]quinolin-2(1H)-one and determining a metabolic profile therefore.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 15:00:50 ON 01 FEB 2008)

     FILE 'REGISTRY' ENTERED AT 15:01:15 ON 01 FEB 2008
L1              STRUCTURE UPLOADED
L2            0 S L1 EXA
L3            2 S L1 EXA FULL

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:02:32 ON 01 FEB
     2008
L4            0 S L2
L5           41 S L3
L6            2 S L5 AND (CMAX OR AUC)

=> s l5 and (cancer or tumor)
L7           27 L5 AND (CANCER OR TUMOR)

=> s l7 and "tyrosine kinase"
L8           23 L7 AND "TYROSINE KINASE"

=> d l8 1-23 ibib, abs

L8   ANSWER 1 OF 23  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:       2006:1225966  CAPLUS
DOCUMENT NUMBER:        146:722
TITLE:                  Methods for treating drug resistant cancer
INVENTOR(S):            Michelson, Glenn C.; Chan, Vivien W.; Heise, Carla C.;
                        Wiesmann, Marion; Dawes, Timothy D.
PATENT ASSIGNEE(S):     Novartis AG, USA
SOURCE:                 PCT Int. Appl., 151pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:          Patent
LANGUAGE:               English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    ---------------------    --------
     WO 2006124413        A2    20061123    WO 2006-US17922          20060510
     WO 2006124413        A3    20070607
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
```

SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2006247803	A1	20061123	AU 2006-247803		20060510
PRIORITY APPLN. INFO.:			US 2005-680722P	P	20050513
			WO 2006-US17922	W	20060510

OTHER SOURCE(S): MARPAT 146:722

AB This invention pertains generally to methods of treating cancer. More specifically, the invention pertains to methods and 4-amino substituted quinolinone benzimidazolyl compds. such as 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one compds. and pharmaceutical formulations comprising such compds. for treating drug-resistant cancer and patients with drug resistant cancer.

L8 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:763835 CAPLUS
DOCUMENT NUMBER: 145:202872
TITLE: Treatment of metastasized tumors
INVENTOR(S): Lopes De Menezes, Daniel; Heise, Carla; Xin, Xiaohua
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 101pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2006081445	A2	20060803	WO 2006-US2979		20060127
WO 2006081445	A3	20070111			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
AU 2006208012	A1	20060803	AU 2006-208012		20060127
CA 2596084	A1	20060803	CA 2006-2596084		20060127
US 2006183750	A1	20060817	US 2006-342257		20060127
EP 1845990	A2	20071024	EP 2006-733986		20060127
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
KR 2007118596	A	20071217	KR 2007-719428		20070824
NO 2007004360	A	20071025	NO 2007-4360		20070827
PRIORITY APPLN. INFO.:			US 2005-647568P	P	20050127
			US 2005-669245P	P	20050406
			US 2005-722053P	P	20050929
			WO 2006-US2979	W	20060127

OTHER SOURCE(S): MARPAT 145:202872

AB Methods of treating metastatic cancer such as metastasized tumors include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a

subject. The compound, tautomer, salt of the compound, salt of the tautomer, or mixture thereof may be used to prepare medicaments for treating metastatic cancer. The variable A has the values defined herein.

L8 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:428803 CAPLUS
DOCUMENT NUMBER: 141:1211
TITLE: Methods of treating cancer with a methylpiperazinyl benzimidazolyl quinolinone and related methods
INVENTOR(S): Machajewski, Timothy D.; Hannah, Alison; Harwood, Eric; Haroldsen, Peter; Heise, Carla C.; Samara, Emil; Shang, Xiao; Vora, Jayesh; Zhu, Shuguang
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043389	A2	20040527	WO 2003-US35806	20031112
WO 2004043389	A3	20040805		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501932	A1	20040527	CA 2003-2501932	20031112
AU 2003290699	A1	20040603	AU 2003-290699	20031112
US 2004220196	A1	20041104	US 2003-706328	20031112
EP 1565187	A2	20050824	EP 2003-783281	20031112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016229	A	20051004	BR 2003-16229	20031112
CN 1711088	A	20051221	CN 2003-80103178	20031112
JP 2006511616	T	20060406	JP 2005-507133	20031112
NZ 539425	A	20071130	NZ 2003-539425	20031112
MX 2005PA04754	A	20050802	MX 2005-PA4754	20050503
IN 2005KN00793	A	20060303	IN 2005-KN793	20050503
NO 2005002760	A	20050720	NO 2005-2760	20050607

PRIORITY APPLN. INFO.:

US 2002-426107P	P	20021113
US 2002-426204P	P	20021113
US 2002-426282P	P	20021113
US 2003-460328P	P	20030403
US 2003-460369P	P	20030403
US 2003-460493P	P	20030403
US 2003-517915P	P	20031107
WO 2003-US35806	W	20031112

AB Methods of treating cancer using 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one (I) are provided. In particular, the methods are effective for the treatment of solid tumors or leukemias, including prostate, colorectal, breast, multiple myeloma, pancreatic, small cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, or myelo-proliferative disease. Further provided are methods of measuring the amount of I and determining a metabolic profile therefore. The growth of both the KM12L4a and MV4;11 xenografts in mice were potently inhibited by I in vivo.

L8 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:182836 CAPLUS
DOCUMENT NUMBER: 140:235711
TITLE: Preparation of benzimidazole quinolinones for inhibiting a serine/threonine kinase
INVENTOR(S): Barsanti, Paul A.; Bussiere, Dirksen; Harrison, Stephen D.; Heise, Carla C.; Jansen, Johanna M.; Jazan, Elisa; Machajewski, Timothy D.; Mcbride, Christopher; McCrea, William R.; Ng, Simon; Ni, Zhi-Jie; Pecchi, Sabina; Pfister, Keith; Ramurthy, Savithri; Renhowe, Paul A.; Shafer, Cynthia M.; Silver, Joel B.; Wagman, Allan; Weismann, Marion
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 570 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018419	A2	20040304	WO 2003-US25990	20030819
WO 2004018419	A3	20040603		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2496164	A1	20040304	CA 2003-2496164	20030819
AU 2003288899	A1	20040311	AU 2003-288899	20030819
EP 1539754	A2	20050615	EP 2003-781286	20030819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013743	A	20050705	BR 2003-13743	20030819
CN 1692112	A	20051102	CN 2003-824565	20030819
JP 2006503919	T	20060202	JP 2005-501762	20030819
IN 2005KN00484	A	20060106	IN 2005-KN484	20050323

PRIORITY APPLN. INFO.:		
US 2002-405729P	P	20020823
US 2002-426107P	P	20021113
US 2002-426226P	P	20021113
US 2002-426282P	P	20021113
US 2002-428210P	P	20021121
US 2003-460327P	P	20030403
US 2003-460328P	P	20030403
US 2003-460493P	P	20030403
US 2003-478916P	P	20030616
US 2003-484048P	P	20030701
WO 2003-US25990	W	20030819

OTHER SOURCE(S): MARPAT 140:235711
GI



I



II

AB The title compds. [I and II; A, B, C, and D = C, N; W, X, Y and Z = C, N and at least one of W, X, Y, and Z = N; R1-R8 = H, halo, CN, NO2, etc.; R9 = H, (un)substituted alkyl, aryl, etc.; R10 = H; or NR9R10 = 5-7 membered ring], useful for inhibiting various enzymes and treating various conditions, were prepared E.g., a multi-step synthesis of 4-amino-3-(benzimidazol-2-yl)-6-(4-methylpiperazinyl)hydroquinolin-2-one, was given. The majority of the exemplary compds. I displayed an IC50 of less than 10 μM with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, Cdk4, MEK1, NEK-2, CHK2, CK1ε, Raf, Fyn, Lck, Rsk2, PAR-1, c-Kit, c-ABL, p60src, FGFR3, FLT-3, PDGFRα, and PDGFRβ. In addition, many of the exemplary compds. exhibited IC50 values in the nM range and show potent activity with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR3, c-Kit, c-ABL, FLT-3, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, MEK1, CHK2, Fyn, Lck, Rsk2, PAR-1, PDGFRα, and PDGFRβ with IC50 values of less than 1 μM.

L8 ANSWER 5 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2007:83463 USPATFULL

TITLE: Use of tyrosine kinase inhibitor to treat diabetes

INVENTOR(S): Hagerkvist, Robert Per, Hoganasgatan 7B, Uppsala, SWEDEN 75330
Welsh, Nils Richard, Uppsala, SWEDEN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2007072932	A1	20070329	
APPLICATION INFO.:	US 2004-556984	A1	20040526	(10)
	WO 2004-EP5679		20040526	
			20060622	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-12086	20030527
	GB 2004-2682	20040206

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1-10
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 857
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of a c-Abl-, PDGF-R-, or c-kit-tyrosine kinase inhibitor, e.g. 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of diabetes, e.g. type I diabetes, type II diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2006:253838 USPATFULL
TITLE: Combinations for the treatment of cancer
INVENTOR(S): Chang, David, Calabasas, CA, UNITED STATES
PATENT ASSIGNEE(S): Amgen Inc, Thousand Oaks, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006216288	A1	20060928	
APPLICATION INFO.:	US 2006-386271	A1	20060321	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2005-664381P	20050322	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AMGEN INC., MAIL STOP 28-2-C, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799, US
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2006:215594 USPATFULL
TITLE: Treatment of metastasized tumors
INVENTOR(S): Menezes, Daniel Lopes De, Emeryville, CA, UNITED STATES
Heise, Carla, Benicia, CA, UNITED STATES
Xin, Xiaohua, Palo Alto, CA, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006183750	A1	20060817	
APPLICATION INFO.:	US 2006-342257	A1	20060127	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2005-647568P	20050127	(60)
	US 2005-669245P	20050406	(60)
	US 2005-722053P	20050929	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 2547
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of treating metastatic cancer such as metastasized tumors include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The compound, tautomer, salt of the compound, salt of the tautomer, or mixture thereof may be used to prepare medicaments for treating metastatic cancer. The variable A has the values defined herein. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2005:299638 USPATFULL
TITLE: Inhibition of FGFR3 and treatment of multiple myeloma
INVENTOR(S): Cai, Shaopei, Seattle, WA, UNITED STATES
Chou, Joyce, El Cerrito, CA, UNITED STATES
Harwood, Eric, Seattle, WA, UNITED STATES
Heise, Carla C., Benicia, CA, UNITED STATES
Machajewski, Timothy D., Martinez, CA, UNITED STATES
Ryckman, David, Bellevue, WA, UNITED STATES
Shang, Xiao, Bellevue, WA, UNITED STATES
Wiesmann, Marion, Brisbane, CA, UNITED STATES
Zhu, Shuguang, Shoreline, WA, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005261307	A1	20051124
APPLICATION INFO.:	US 2004-983174	A1	20041105 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-644055, filed on 19 Aug 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-517915P	20031107 (60)
	US 2003-526426P	20031202 (60)
	US 2003-526425P	20031202 (60)
	US 2004-546017P	20040219 (60)
	US 2002-405729P	20020823 (60)
	US 2002-426107P	20021113 (60)
	US 2002-426226P	20021113 (60)
	US 2002-426282P	20021113 (60)
	US 2002-428210P	20021121 (60)
	US 2003-460328P	20030403 (60)
	US 2003-460493P	20030403 (60)
	US 2003-460327P	20030403 (60)
	US 2003-478916P	20030616 (60)
	US 2003-484048P	20030701 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Page(s)
LINE COUNT: 17221

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2005:293608 USPATFULL

TITLE: Combination therapy with CHK1 inhibitors

INVENTOR(S): Gesner, Thomas G., Kensington, CA, UNITED STATES
Barsanti, Paul A., Pleasant Hill, CA, UNITED STATES
Harrison, Stephen D., Albany, CA, UNITED STATES
Ni, Zhi-Jie, Fremont, CA, UNITED STATES
Brammeier, Nathan M., Walnut Creek, CA, UNITED STATES
Zhou, Yasheen, Moraga, CA, UNITED STATES
Le, Vincent P., San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S): CHIRON CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005256157	A1	20051117
APPLICATION INFO.:	US 2005-41191	A1	20050121 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-644055, filed on 19 Aug 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-538984P	20040123 (60)
	US 2002-405729P	20020823 (60)
	US 2002-426282P	20021113 (60)
	US 2002-426107P	20021113 (60)
	US 2002-426226P	20021113 (60)
	US 2002-428210P	20021121 (60)
	US 2003-460493P	20030403 (60)
	US 2003-460328P	20030403 (60)
	US 2003-460327P	20030403 (60)
	US 2003-478916P	20030616 (60)
	US 2003-484048P	20030701 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US

NUMBER OF CLAIMS: 32

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 16679

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2005:275261 USPATFULL
TITLE: Modulation of inflammatory and metastatic processes
INVENTOR(S): Heise, Carla, Benicia, CA, UNITED STATES
Lee, Sang H., Waltham, MA, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005239825	A1	20051027	
APPLICATION INFO.:	US 2005-61386	A1	20050218	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2004-546395P	20040220	(60)
	US 2004-547103P	20040223	(60)
	US 2004-554771P	20040319	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 5172
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of using compounds having Structure I or the salts or tautomers of the compounds in the treatment of disorders relating to cell adhesion and metastatic processes are presented herein. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2005:241451 USPATFULL
TITLE: Quinolinone derivatives
INVENTOR(S): Renhowe, Paul A., Danville, CA, UNITED STATES
Shafer, Cynthia M., Moraga, CA, UNITED STATES
Machajewski, Timothy D., Martinez, CA, UNITED STATES
Pecchi, Sabina, Oakland, CA, UNITED STATES
McBride, Christopher, Oakland, CA, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005209456	A1	20050922	
APPLICATION INFO.:	US 2005-92137	A1	20050329	(11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-886950, filed on 8 Jul 2004, PENDING Continuation of Ser. No. US 2002-284017, filed on 30 Oct 2002, GRANTED, Pat. No. US 6774237 Continuation of Ser. No. US 2001-951265, filed on 11 Sep 2001, GRANTED, Pat. No. US 6605617			

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-232159P	20000911	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 5434
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for synthesizing a 4-amino substituted quinolinone includes reacting a substituted or unsubstituted 2-benzimidazolyl-2-acetate with a substituted or unsubstituted 2-aminobenzonitrile in the presence of a

base or an acid. A 4-amino substituted quinolinone compound is formed by the reaction, and the 4-amino substituted quinolinone compound comprises a benzimidazole group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2005:241242 USPATFULL
TITLE: Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
INVENTOR(S): Cai, Shaopei, Seattle, WA, UNITED STATES
Chou, Joyce, El Cerrito, CA, UNITED STATES
Harwood, Eric, Seattle, WA, UNITED STATES
Machajewski, Timothy, Martinez, CA, UNITED STATES
Ryckman, David, Bellevue, WA, UNITED STATES
Shang, Xiao, Bellevue, WA, UNITED STATES
Zhu, Shuguang, Shoreline, WA, UNITED STATES
Okhamafe, Augustus O., Concord, CA, UNITED STATES
Tesconi, Marc S., Monroe, NY, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005209247	A1	20050922
APPLICATION INFO.:	US 2004-982543	A1	20041105 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-517915P	20031107 (60)
	US 2003-526425P	20031202 (60)
	US 2003-526426P	20031202 (60)
	US 2004-546017P	20040219 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 7116
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R.sup.1-R.sup.9 and R.sup.12-R.sup.14 are as defined herein ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2005:234162 USPATFULL
TITLE: Benzimidazole quinolinones and uses thereof
INVENTOR(S): Barsanti, Paul A., Pleasant Hill, CA, UNITED STATES
Bussiere, Dirksen, San Leandro, CA, UNITED STATES
Harrison, Stephen D., Albany, CA, UNITED STATES
Heise, Carla C., Benicia, CA, UNITED STATES
Jansen, Johanna M., San Francisco, CA, UNITED STATES
Jazan, Elisa, Berkeley, CA, UNITED STATES
Machajewski, Timothy D., Martinez, CA, UNITED STATES
McBride, Christopher, Oakland, CA, UNITED STATES
McCrea, William R. JR., Berkeley, CA, UNITED STATES
Ng, Simon, Walnut Creek, CA, UNITED STATES
Ni, Zhi-Jie, Fremont, CA, UNITED STATES
Pecchi, Sabina, Oakland, CA, UNITED STATES
Pfister, Keith B., San Ramon, CA, UNITED STATES
Ramurthy, Savithri, Walnut Creek, CA, UNITED STATES
Renhowe, Paul A., Danville, CA, UNITED STATES

Shafer, Cynthia M., El Sobrante, CA, UNITED STATES
Silver, Joel B., Santa Cruz, CA, UNITED STATES
Wagman, Allan S., Belmont, CA, UNITED STATES
Wiesmann, Marion, Brisbane, CA, UNITED STATES
Wayman, Kelly, San Rafael, CA, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005203101	A1	20050915
APPLICATION INFO.:	US 2004-839793	A1	20040505 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2003-644055, filed on 19 Aug 2003, PENDING

PRIORITY INFORMATION:	NUMBER	DATE
	US 2002-405729P	20020823 (60)
	US 2002-426107P	20021113 (60)
	US 2002-426226P	20021113 (60)
	US 2002-426282P	20021113 (60)
	US 2002-428210P	20021121 (60)
	US 2003-460328P	20030403 (60)
	US 2003-460493P	20030403 (60)
	US 2003-460327P	20030403 (60)
	US 2003-478916P	20030616 (60)
	US 2003-484048P	20030701 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 14866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of treating cancer include contacting a cancer cell with 4-amino-5-fluoro-3-(5-piperazin-1-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one, 4-amino-5-fluoro-3-[5-(4-methyl-4-oxidopiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, tautomers thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable salts of the tautomers thereof, or a mixture thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2005:159189 USPATFULL
TITLE: Methods for synthesizing quinolinone compounds
INVENTOR(S): Cai, Shaopei, Seattle, WA, UNITED STATES
Chou, Joyce, El Cerrito, CA, UNITED STATES
Harwood, Eric, Seattle, WA, UNITED STATES
Machajewski, Timothy, Martinez, CA, UNITED STATES
Ryckman, David, Bellevue, WA, UNITED STATES
Shang, Xiao, Bellevue, WA, UNITED STATES
Zhu, Shuguang, Shoreline, WA, UNITED STATES
Okhamafe, Augustus O., Concord, CA, UNITED STATES
Tesconi, Marc S., Monroe, NY, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005137399	A1	20050623
APPLICATION INFO.:	US 2004-982757	A1	20041105 (10)

	NUMBER	DATE

PRIORITY INFORMATION: US 2003-517915P 20031107 (60)
US 2003-526425P 20031202 (60)
US 2003-526426P 20031202 (60)
US 2004-546017P 20040219 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US
NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
LINE COUNT: 2006
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of synthesizing a substituted or unsubstituted 4-amino-3-benzimidazolyl quinolinone compound includes reacting a first compound having the formula I with a second compound having the formula II in a suitable solvent in the presence of a sodium or potassium salt of a base. The first compound and the second compound have the following structures where the variables have the values described herein: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2005:63630 USPATFULL
TITLE: Quinolinone derivatives
INVENTOR(S): Renhowe, Paul A., Danville, CA, UNITED STATES
Pecchi, Sabina, Oakland, CA, UNITED STATES
Machajewski, Timothy D., Martinez, CA, UNITED STATES
Shafer, Cynthia M., El Sobrante, CA, UNITED STATES
Taylor, Clarke, Albany, CA, UNITED STATES
McCrea, William R., Berkeley, CA, UNITED STATES
McBride, Christopher, Oakland, CA, UNITED STATES
Jazan, Elisa, Richmond, CA, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005054672	A1	20050310
APPLICATION INFO.:	US 2004-886950	A1	20040708 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-284017, filed on 30 Oct 2002, GRANTED, Pat. No. US 6774237 Continuation of Ser. No. US 2001-951265, filed on 11 Sep 2001, GRANTED, Pat. No. US 6605617

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232159P	20000911 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Young J. Suh, Chiron Corporation, P.O. Box 8097, Emeryville, CA, 94662
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 5757
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Organic compounds having the formula I are provided where the variables have the values described herein. ##STR1##

Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2005:44347 USPATFULL
TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
INVENTOR(S): Boyer, Stephen, Hilden, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Bethany, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Wilhelm, Scott, Orange, CT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005038080	A1	20050217	
APPLICATION INFO.:	US 2004-895985	A1	20040722	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-489102P	20030723	(60)
	US 2004-540326P	20040202	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 2492
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of Formula (I): ##STR1##

salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by raf, VEGFR, PDGFR, p38 and flt-3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2004:280895 USPATFULL
TITLE: Methods of treating cancer and related methods
INVENTOR(S): Hannah, Alison, Sebastopol, CA, UNITED STATES
Harwood, Eric, Seattle, WA, UNITED STATES
Haroldsen, Peter, Pacifica, CA, UNITED STATES
Heise, Carla, Benecia, CA, UNITED STATES
Machajewski, Timothy, Martinez, CA, UNITED STATES
Samara, Emil, Danville, CA, UNITED STATES
Shang, Xiao, Bellevue, WA, UNITED STATES
Vora, Jayesh, Martinez, CA, UNITED STATES
Zhu, Shuguang, Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004220196	A1	20041104	
APPLICATION INFO.:	US 2003-706328	A1	20031112	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-460369P	20030403	(60)
	US 2003-460493P	20030403	(60)
	US 2003-460328P	20030403	(60)
	US 2002-426204P	20021113	(60)
	US 2002-426282P	20021113	(60)

	US 2002-426107P 20021113 (60)
	US 2003-517915P 20031107 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097
NUMBER OF CLAIMS:	58
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Page(s)
LINE COUNT:	2045

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of treating cancer using 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one are provided. In particular, the methods are effective for the treatment of solid tumors or leukemias, including prostate, colorectal, breast, multiple myeloma, pancreatic, small cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, or myelo-proliferative disease. Further provided are methods of measuring the amount of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one and determining a metabolic profile therefore.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 23 USPATFULL on STN

ACCESSION NUMBER:	2004:127561 USPATFULL
TITLE:	Quinolinone derivatives
INVENTOR(S):	Renhowe, Paul A., Danville, CA, UNITED STATES Pecchi, Sabina, Oakland, CA, UNITED STATES Machajewski, Timothy D., Martinez, CA, UNITED STATES Shafer, Cynthia M., El Sobrante, CA, UNITED STATES Taylor, Clarke, Ann Arbor, MI, UNITED STATES McCrea, William R., JR., Berkeley, CA, UNITED STATES McBride, Christopher, Oakland, CA, UNITED STATES Jazan, Elisa, Richmond, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004097545	A1	20040520
	US 6800760	B2	20041005
APPLICATION INFO.:	US 2003-613411	A1	20030703 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-951265, filed on 11 Sep 2001, GRANTED, Pat. No. US 6605617

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232159P	20000911 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Chiron Corporation, Intellectual Property, P.O. Box 8097, Emeryville, CA, 94662-8097
NUMBER OF CLAIMS:	37
EXEMPLARY CLAIM:	1
LINE COUNT:	6582

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Organic compounds having the formulas I and II are provided where the variables have the values described herein. ##STR1##

Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2004:121119 USPATFULL
TITLE: Benzimidazole quinolinones and uses thereof
INVENTOR(S): Barsanti, Paul A., Walnut Creek, CA, UNITED STATES
Bussiere, Dirksen, San Leandro, CA, UNITED STATES
Harrison, Stephen D., Albany, CA, UNITED STATES
Heise, Carla C., Benicia, CA, UNITED STATES
Jansen, Johanna M., San Francisco, CA, UNITED STATES
Jazan, Elisa, Richmond, CA, UNITED STATES
Michajewski, Timothy D., Martinez, CA, UNITED STATES
McBride, Christopher, Oakland, CA, UNITED STATES
McCrea, William R., JR., Berkeley, CA, UNITED STATES
Ng, Simon, Walnut Creek, CA, UNITED STATES
Ni, Zhi-Jie, Fremont, CA, UNITED STATES
Pecchi, Sabina, Oakland, CA, UNITED STATES
Pfister, Keith B., San Ramon, CA, UNITED STATES
Ramurthy, Savithri, Walnut Creek, CA, UNITED STATES
Renhowe, Paul A., Danville, CA, UNITED STATES
Shafer, Cynthia M., El Sobrante, CA, UNITED STATES
Silver, Joel B., Concord, NH, UNITED STATES
Wagman, Allan S., Belmont, CA, UNITED STATES
Wiesmann, Marion, Brisbane, CA, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004092535	A1	20040513	
APPLICATION INFO.:	US 2003-644055	A1	20030819	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-405729P	20020823	(60)
	US 2002-426107P	20021113	(60)
	US 2002-426226P	20021113	(60)
	US 2002-426282P	20021113	(60)
	US 2002-428210P	20021121	(60)
	US 2003-460328P	20030403	(60)
	US 2003-460493P	20030403	(60)
	US 2003-460327P	20030403	(60)
	US 2003-478916P	20030616	(60)
	US 2003-484048P	20030701	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097
NUMBER OF CLAIMS: 68
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 18050
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2004:7861 USPATFULL

TITLE: Quinolinone derivatives
INVENTOR(S): Renhowe, Paul A., Danville, CA, UNITED STATES
Pecchi, Sabina, Oakland, CA, UNITED STATES
Machajewski, Timothy D., Martinez, CA, UNITED STATES
Shafer, Cynthia M., El Sobrante, CA, UNITED STATES
Taylor, Clarke, Ann Arbor, MI, UNITED STATES
McCrea, William R., JR., Berkeley, CA, UNITED STATES
McBride, Christopher, Oakland, CA, UNITED STATES
Jazan, Eliza, Richmond, CA, UNITED STATES
PATENT ASSIGNEE(S): CHIRON CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004006101	A1	20040108
	US 6762194	B2	20040713
APPLICATION INFO.:	US 2003-387355	A1	20030312 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-284017, filed on 30 Oct 2002, PENDING Continuation of Ser. No. US 2001-951265, filed on 11 Sep 2001, GRANTED, Pat. No. US 6605617

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232159P	20000911 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Steven W. Collier, Chiron Corporation, P.O. Box 8097, Emeryville, CA, 94662
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
LINE COUNT: 5740
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Organic compounds having the formulas I and II are provided where the variables have the values described herein. ##STR1##

Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2003:226411 USPATFULL
TITLE: Quinolinone derivatives
INVENTOR(S): Renhowe, Paul A., Danville, CA, UNITED STATES
Pecchi, Sabina, Oakland, CA, UNITED STATES
Machajewski, Timothy D., Martinez, CA, UNITED STATES
Shafer, Cynthia M., El Sobrante, CA, UNITED STATES
Taylor, Clarke, Ann Arbor, MI, UNITED STATES
McCrea Jr, William R., Berkeley, CA, UNITED STATES
McBride, Christopher, Oakland, CA, UNITED STATES
Jazan, Elisa, Richmond, CA, UNITED STATES
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003158224	A1	20030821
	US 6774237	B2	20040810
APPLICATION INFO.:	US 2002-284017	A1	20021030 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-951265, filed on 11 Sep 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232159P	20000911 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Steven W. Collier, Chiron Corporation, P.O. Box 8097, Emeryville, CA, 94662
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
LINE COUNT: 5881
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Organic compounds having the formulas I and II are provided where the variables have the values described herein. ##STR1##

Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2003:38371 USPATFULL
TITLE: Quinolinone derivatives
INVENTOR(S): Renhowe, Paul A., Danville, CA, UNITED STATES
Pecchi, Sabina, Oakland, CA, UNITED STATES
Machajewski, Timothy D, Martinez, CA, UNITED STATES
Shafer, Cynthia M., El Sobrante, CA, UNITED STATES
Taylor, Clarke, Ann Arbor, MI, UNITED STATES
McCrea, William R., JR., Berkeley, CA, UNITED STATES
McBride, Christopher, Oakland, CA, UNITED STATES
Jazan, Elisa, Richmond, CA, UNITED STATES
PATENT ASSIGNEE(S): Chiron Coporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003028018	A1	20030206
APPLICATION INFO.:	US 2002-116117	A1	20020405 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-951265, filed on 11 Sep 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232159P	20000911 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property Law Dept., PO Box 8097, Emeryville, CA, 94662
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
LINE COUNT: 6573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Organic compounds having the formulas I and II are provided where the variables have the values described herein. ##STR1##

Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in

need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2002:199281 USPATFULL
TITLE: Quinolinone derivatives
INVENTOR(S): Renhowe, Paul A., Danville, CA, UNITED STATES
Pecchi, Sabina, Oakland, CA, UNITED STATES
Machajewski, Timothy D., Martinez, CA, UNITED STATES
Shafer, Cynthia M., El Sobrante, CA, UNITED STATES
Taylor, Clarke, Ann Arbor, MI, UNITED STATES
McCrea, William R., JR., Berkeley, CA, UNITED STATES
McBride, Christopher, Oakland, CA, UNITED STATES
Jazan, Elisa, Richmond, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002107392	A1	20020808	
	US 6605617	B2	20030812	
APPLICATION INFO.:	US 2001-951265	A1	20010911	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232159P	20000911 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: David Lentini, CHIRON CORPORATION, 4560 Horton Street, Emeryville, CA, 94608-2916
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
LINE COUNT: 6588
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Organic compounds having the formulas I and II are provided where the variables have the values described herein. ##STR1##

Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:00:50 ON 01 FEB 2008)

FILE 'REGISTRY' ENTERED AT 15:01:15 ON 01 FEB 2008
L1 STRUCTURE UPLOADED
L2 0 S L1 EXA
L3 2 S L1 EXA FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:02:32 ON 01 FEB 2008
L4 0 S L2
L5 41 S L3
L6 2 S L5 AND (CMAX OR AUC)
L7 27 S L5 AND (CANCER OR TUMOR)
L8 23 S L7 AND "TYROSINE KINASE"

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	92.93	159.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

STN INTERNATIONAL LOGOFF AT 15:09:27 ON 01 FEB 2008